All In Biotech

Drug Trial Radar · NCT07819097

A Study to Learn About the Safety and Immune Responses of RSVpreF in Older Adults

AN INTERVENTIONAL PHASE 3 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN PARTICIPANTS 60 YEARS OF AGE AND OLDER

Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Sep 9, 2026

Primary completion

May 16, 2027

Study completion May 16, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the safety, tolerability, and immune response of the RSVpreF vaccine in healthy older adults. Participants will take part in this study for about 6 months. The study will include people in China and the United States. In China, participants will receive either RSVpreF or placebo. A placebo is a dummy vaccine with no active ingredient, but it looks just like the vaccine being studied. In the United States, all participants will receive RSVpreF. Researchers will check for any reactions. They will also check blood test results to learn how the body responds to the vaccine. The main questions the study aims to answer are: * What local reactions and systemic events (body-wide symptoms) do participants have after a RSVpreF vaccination? * What medical problems do participants have after a RSVpreF vaccination? * Researchers will compare antibody levels from blood tests between the China cohort and the US cohort. An antibody is a substance in the body that try to fight off an infection or foreign substance. Participants will: * Have a screening visit to make sure they qualify for the study (participants in China will have this visit before the day of vaccination) * Receive the RSVpreF vaccination (or a placebo injection if in the China cohort) once at Visit 1. * Have a telephone or clinic visit 1 week later to assess local reactions and systemic events. * Have a clinic visit a month after vaccination for a checkup and tests. * Have a telephone or clinic visit 6 months after vaccination for a health check. * Have a blood test at screening (if in the China cohort only), on the day of vaccination and 1 month after vaccination.

Conditions

  • Adult
  • Healthy Participants

Interventions

  • RSVpreFBiological

    Single Dose

  • PlaceboOther

    Single Dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants reporting local reactions: pain at the injection site, redness, and swellingTime frame: Within 7 days after vaccination
  2. Percentage of participants reporting systemic events: fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain, and joint painTime frame: Within 7 days after vaccination
  3. Percentage of participants reporting adverse events (AEs)Time frame: Within 1 month after vaccination
  4. Percentage of participants reporting serious adverse events (SAEs)Time frame: Through 6 months after vaccination
  5. Percentage of participants reporting newly diagnosed chronic medical conditions (NDCMCs)Time frame: Through 6 months after vaccination
  6. RSV A and RSV B neutralizing antibody levels before vaccination and 1 month after vaccinationTime frame: Before vaccination and 1 month after vaccination
  7. Geometric mean fold rise in RSV A and RSV B neutralizing antibody levels from before vaccination to 1 month after vaccinationTime frame: Before vaccination to 1 month after vaccination

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • Headlands Research - Scottsdale

    Scottsdale, Arizona · Not yet recruiting

  • Orange County Research Center

    Lake Forest, California · Not yet recruiting

  • Artemis Institute for Clinical Research

    Riverside, California · Not yet recruiting

  • Clinical Research Consulting, LLC

    Milford, Connecticut · Not yet recruiting

  • George Washington University

    Washington D.C., District of Columbia · Not yet recruiting

  • Solaris Clinical Research

    Meridian, Idaho · Not yet recruiting

  • MediSphere Medical Research Center, LLC

    Evansville, Indiana · Not yet recruiting

  • IMA Clinical Research Warren

    Warren Township, New Jersey · Not yet recruiting

  • Remington-Davis, Inc

    Columbus, Ohio · Not yet recruiting

  • DM Clinical Research - Philadelphia

    Philadelphia, Pennsylvania · Not yet recruiting

  • J. Lewis Research, Inc. / Foothill Family Clinic Draper

    Draper, Utah · Not yet recruiting

  • J. Lewis Research, Inc. / Jordan River Family Medicine

    South Jordan, Utah · Not yet recruiting

  • Charlottesville Medical Research Center, LLC

    Charlottesville, Virginia · Not yet recruiting

  • Clinical Research Partners, LLC

    Richmond, Virginia · Not yet recruiting

  • Huashan Hospital Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.